表紙
市場調查報告書

全球液態切片市場

Liquid Biopsy Markets by Cancer Type and by Usage Type and with Potential Market Size Analysis. with Executive and Consultant Guides and Including Customized Forecasting and Analysis 2020-2024

出版商 Howe Sound Research 商品編碼 461040
出版日期 內容資訊 英文 409 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球液態切片市場 Liquid Biopsy Markets by Cancer Type and by Usage Type and with Potential Market Size Analysis. with Executive and Consultant Guides and Including Customized Forecasting and Analysis 2020-2024
出版日期: 2019年10月01日內容資訊: 英文 409 Pages
簡介

本報告提供全球液態切片市場相關調查分析,15個國家、4個地區為對象,市場概要,市場趨勢,市場預測等系統性資訊。

第1章 簡介與市場定義

  • 所謂液態切片
  • 定序革命
  • 市場定義
  • 調查手法
  • 液態切片的支出預測

第2章 市場概要

  • 動態市場上企業
  • 活體組織切片的使用
  • 活體組織切片網站
  • 目前情形:活體組織切片分析
  • 癌症的證據:液態切片技術
  • 癌症治療協議具批判性
  • 產業結構
  • 主要企業的簡介
    • Qiagen
    • Agena Bioscience
    • Angle plc
    • ApoCell
    • Biocept
    • BioFluidica
    • Bio-Rad Laboratories
    • Boreal Genomics
    • Chronix Biomedical
    • Clearbridge BioMedics
    • Cynvenio
    • Cytolumina Technologies Corp
    • CytoTrack
    • Diagnologix LLC
    • Epic Sciences
    • Exosome Diagnostics
    • Exosome Sciences
    • Fluidigm Corp
    • Fluxion Biosciences
    • Genomic Health
    • GRAIL
    • Guardant Health
    • HansaBiomed
    • Horizon Discovery
    • iCellate
    • Illumina
    • Inivata
    • Janssen Diagnostics
    • Molecular MD
    • Myriad Genetics
    • Natera
    • New Oncology
    • Roche Diagnostics
    • RainDance Technologies
    • Rarecells SAS
    • Silicon Biosystems
    • Sysmex Inostics
    • SRI International
    • Thermo Fisher
    • Trovagene
    • Freenome
    • Personal Genome Diagnostics
    • MDx Health
    • Bioarray Genetics
    • Oncocyte
    • Circulogene
    • Integrated Diagnostics
    • Bio Cartis
    • Clinical Genomics
    • OncoDNA

第3章 市場趨勢

  • 成長促進因素
  • 成長阻礙因素
  • 檢查裝置與自動化
  • 診斷技術的發展

第4章 液態切片的最近的發展

第5章 各國市場規模:北美

  • 美國
  • 加拿大

第6章 各國市場:歐洲

  • 法國
  • 德國
  • 英國
  • 西班牙
  • 義大利
  • 俄羅斯
  • 其他,舊蘇聯

第7章 各國市場:亞太地區

  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 其他

第8章 各國市場:南美,非洲、中東

  • 巴西
  • 墨西哥
  • 其他南美
  • 非洲、中東

第9章 全球市場摘要

  • 全球市場

第10章 潛在的市場機會規模

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

OVERVIEW:

The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report.

What is the size of the huge screening opportunity? This huge opportunity is explored by country with an astounding result for the Global Potential Market Size!

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread SCREENING FOR ALL TYPES OF CANCERS WITH A BLOOD TEST.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has JUST MOVED OUT OF THE DEVELOPMENT PHASE AND INTO THE GROWTH PHASE. The impact on the health care industry is enormous. The report forecasts the market size out to 2024. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, Precancer, Melanoma and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

  • i. Liquid Biopsy Market - Strategic Situation Analysis
  • ii. Guide for Executives, Marketing, Sales and Business Development Staff
  • iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. What is Liquid Biopsy?
  • 1.2. The Sequencing Revolution
  • 1.3. Market Definition
    • 1.3.1. Revenue Market Size
  • 1.4. Methodology
    • 1.4.1. Authors
    • 1.4.2. Sources
  • 1.5. A Spending Perspective on Liquid Biopsy
    • 1.5.1. An Historical Look at Clinical Testing

2. Market Overview

  • 2.1. Players in a Dynamic Market
    • 2.1.1. Academic Research Lab
    • 2.1.2. Diagnostic Test Developer
    • 2.1.3. Genomic Instrumentation Supplier
  • 2.1.3.1. Cell Separation and Viewing Instrumentation Supplier
    • 2.1.4. Pharmaceutical/Reagent Supplier
    • 2.1.5. Independent Testing Lab
    • 2.1.6. Public National/regional lab
    • 2.1.7. Hospital lab
    • 2.1.8. Physician Lab
    • 2.1.9. Audit Body
    • 2.1.10. Certification Body
  • 2.2. Using Biopsies
    • 2.2.1. Cancer
    • 2.2.2. Precancerous conditions
    • 2.2.3. Inflammatory conditions
  • 2.3. Biopsy Sites
  • 2.4. The Situation Today-Biopsy Analysis
  • 2.5. Evidence of Cancer - Liquid Biopsy Technology
    • 2.5.1. The Big Picture on Liquid Biopsy Technology
    • 2.5.2. The Role of CTCs
      • 2.5.2.1. Types of CTCs
      • 2.5.2.2. CellSearch Detection- Ultimate Sensitivity
      • 2.5.2.3. Epic Sciences Detection- Imaging Takes the Lead
      • 2.5.2.4. Maintrac Detection-The Microscope
      • 2.5.2.5. Other Methods
    • 2.5.3. ctDNA-Going Mainstream?
    • 2.5.4. Exosomes and Micro Vesicles-New Kid on the Block
    • 2.5.5. The Multiple Play
  • 2.6. Cancer Treatment Protocol Under Siege
    • 2.6.1. Issues to Liquid Biopsy Adoption-Double Diagnostics
    • 2.6.2. The Cancer Screening Market Opportunity
      • 2.6.2.1. GRAIL-What Is It?
    • 2.6.3. Cancer Management vs. Diagnosis
      • 2.6.3.1. The Role of Risk Assessment
      • 2.6.3.2. Managing Therapy
      • 2.6.3.3. Monitoring Disease-What Is It?
    • 2.6.4. Phases of Adoption-Looking into The Future
    • 2.6.5. The Promise of Liquid Biopsy
  • 2.7. Structure of Industry Plays a Part
    • 2.7.1. Hospital Testing Share
    • 2.7.2. Economies of Scale
      • 2.7.2.1. Hospital vs. Central Lab
    • 2.7.3. Physician Office Lab's
    • 2.7.4. Physician's and POCT
  • 2.8. Profiles of Key Players
    • Abbott Diagnostics
    • AccuraGen Inc
    • Acuamark Diagnostics
    • Admera Health, LLC
    • Agena Bioscience, Inc
    • Agilent
    • Amoy Diagnostics Co., Ltd.
    • Anchor Dx
    • ANGLE plc
    • ApoCell, Inc.
    • ArcherDx, Inc.
    • Asuragen
    • AVIVA Biosciences
    • Baylor Miraca Genetics Laboratories
    • Beckman Coulter, Inc.
    • Becton, Dickinson and Company
    • BGI Genomics Co. Ltd
    • Bioarray Genetics
    • Biocartis
    • Biocept, Inc
    • Biodesix Inc.
    • BioFluidica
    • bioMérieux Diagnostics
    • Bioneer Corporation
    • Bio-Rad Laboratories, Inc
    • Bio-Techne
    • Bioview
    • Bolidics
    • Boreal Genomics
    • Caris Molecular Diagnostics
    • CellMax Life
    • Cepheid (now Danaher)
    • Chronix Biomedical
    • Circulogene
    • Clinical Genomics
    • Cynvenio
    • Cytolumina Technologies Corp.
    • CytoTrack
    • Datar Cancer Genetics Limited
    • Diagenode Diagnostics
    • Diagnologix LLC
    • Enzo Life Sciences, Inc.
    • Epic Sciences
    • Epigenomics AG
    • Eurofins Scientific
    • Exosome Diagnostics
    • Exosome Sciences
    • Fluidigm Corp
    • Fluxion Biosciences
    • Foundation Medicine
    • Freenome
    • GeneFirst Ltd.
    • Genetron Health (Beijing) Co., Ltd
    • Genomic Health
    • GILUPI Nanomedizin
    • Grail, Inc.
    • Guardant Health
    • HansaBiomed
    • HeiScreen
    • Helomics
    • Horizon Discovery
    • iCellate
    • Illumina
    • Incell Dx
    • Inivata
    • Integrated Diagnostics
    • Janssen Diagnostics
    • MDNA Life SCIENCES, Inc
    • MDx Health
    • Menarini Silicon Biosystems
    • Millipore Sigma
    • Miltenyi Biotec
    • miR Scientific
    • Molecular MD
    • Myriad Genetics/Myriad RBM
    • NantHealth, Inc.
    • Natera
    • NeoGenomics
    • New Oncology
    • Novogene Bioinformatics Technology Co., Ltd.
    • Oncocyte
    • OncoDNA
    • Oxford Nanopore Technologies
    • Perkin Elmer
    • Personal Genome Diagnostics
    • PrecisionMed
    • Promega
    • Qiagen Gmbh
    • Quidel
    • Rarecells SAS
    • RareCyte
    • Resolution Biosciences, Inc
    • Roche Molecular Diagnostics
    • Screencell
    • Siemens Healthineers
    • simfo GmbH
    • Singlera Genomics Inc.
    • SRI International
    • Sysmex Inostics
    • Tempus Labs, Inc.
    • Thermo Fisher Scientific Inc.
    • Thrive Earlier Detection
    • Trovagene
    • Volition

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. Non Invasive Game Changer
    • 3.1.2. Lower Cost
    • 3.1.3. Greater Accuracy
    • 3.1.4. Wide Range of Potential Uses
    • 3.1.5. Aging Population
  • 3.2. Factors Limiting Growth
    • 3.2.1. Lower prices
    • 3.2.2. Lack of Standards
    • 3.2.3. Protocol Resistance
    • 3.2.4. Initial Adoption Has No Cost Savings
  • 3.3. Instrumentation and Automation
    • 3.3.1. Instruments Key to Market Share
    • 3.3.2. Bioinformatics Plays a Role.
  • 3.4. Diagnostic Technology Development
    • 3.4.1. Next Generation Sequencing Fuels a Revolution.
    • 3.4.2. Impact of NGS on pricing
    • 3.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4. CGES Testing, A Brave New World
    • 3.4.5. Biochips/Giant magneto resistance based assay

4. Liquid Biopsy Recent Developments

  • 4.1. Recent Developments-Importance and How to Use This Section
    • 4.1.1. Importance of These Developments
    • 4.1.2. How to Use This Section
      • Aethlon Medical Lands Grant for Exosome Isolation Device
      • Biolidics to Develop Liquid Biopsy Breast Cancer Test
      • Liquid Biopsy Equal to Tissue to Indicate Immunotherapy Response
      • Exact Sciences buys Genomic Health
      • Multi-Gene Liquid Biopsy Breast Cancer Panel
      • Bio-Techne receives FDA breakthrough device for prostate cancer liquid biopsy
      • Thrive to Develop Earlier Detection of Multiple Cancer Types
      • Guardant Health Liquid Biopsy Test to be Covered by EviCore
      • Liquid biopsy combines Illumina's ‘ultradeep' sequencing with Grail's machine learning
      • Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services
      • Natera Commercializes Tumor Whole Exome Sequencing from Plasma
      • Sienna Buys Liquid Biopsy & Exosome Isolation Technology
      • Inivata Completes £39.8M Series B Funding Round
      • Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
      • CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials
      • Biodesix Acquires Integrated Diagnostics
      • Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx
      • Bio-Techne to Acquire Exosome Dx for Up to $575M
      • GRAIL Announces Data on Detection of Early-Stage Lung Cancers
      • CellMax Life, IncellDx Partner to Develop Circulating Tumor Cell Tests
      • Personal Genome Diagnostics Nets $75M in Series B Financing
      • Circulogene Licenses Liquid Biopsy Tech to Turkish Lab
      • Liquid Biopsy Firms Move Toward Multianalyte Detection
      • In a first, China approves Amoy's lung cancer liquid biopsy
      • Liquid Biopsy Shows Promise for Colon Cancer
      • Bio-Rad Continues to Advance Digital PCR Tech, Liquid Biopsy Tests Into Commercial
      • Clinical Market
      • Liquid Biopsy Combo Improved Sensitivity for EGFR Mutations in NSCLC
      • Startups race to develop cancer screens from DNA
      • Bristol-Myers, NEA drive cancer test player to $75M round
      • Avalon GloboCare, Da An Gene Collaborate on Liquid Biopsy Diagnostics
      • OncoDNA Inks Russian Distribution Deal With Genext
      • Biocept Prices $15M Public Offering
      • UgenTec, MDxHealth Partner To Develop AI Software for Prostate Cancer Tests
      • Exact Sciences Shares Drop on Threat From Liquid Biopsy
      • Precision for Medicine Acquires ApoCell
      • NeoGenomics to Acquire Genoptix for Cash, Stocks
      • PGDx Liquid Biopsy Assay to be Used in Cancer Drug Study
      • Liquid Biopsy IDs More NSCLC Mutations in Study of Guardant Test
      • Inivata Gets Draft Medicare Coverage Determination for Lung Cancer Test

5. The Global Market for Liquid Biopsy

  • 5.1. Liquid Biopsy-Global Market Overview by Country
    • 5.1.1. Table-Global Market by Country
    • 5.1.2. Chart - Global Market by Country

6. Global Liquid Biopsy Markets-By Type of Cancer

  • 6.1. Global Market by Cancer Type - Overview
    • 6.1.1. Table-Global Market by Cancer Type
    • 6.1.2. Chart-Global Market by Cancer Type-2019/2024 Comparison
    • 6.1.3. Chart-Global Market by Cancer Type-2019
    • 6.1.4. Chart-Global Market by Cancer Type - 2024
    • 6.1.4. Chart-Global Market by Cancer Type-Share by Year
  • 6.2. Liquid Biopsy Breast Cancer
    • 6.2.1. Table Breast Cancer Testing-by Country
    • 6.2.2. Chart - Breast Cancer Testing Growth
  • 6.3. Liquid Biopsy Colorectal Cancer
    • 6.3.1. Table Colorectal Cancer Testing-by Country
    • 6.3.2. Chart - Colorectal Cancer Testing Growth
  • 6.4. Liquid Biopsy Cervical Cancer
    • 6.4.1. Table Cervical Cancer Testing-by Country
    • 6.4.2. Chart - Cervical Cancer Testing Growth
  • 6.5. Liquid Biopsy Lung Cancer
    • 6.5.1. Table Lung Cancer Testing-by Country
    • 6.5.2. Chart - Lung Cancer Testing Growth
  • 6.6. Liquid Biopsy Precancer
    • 6.2.1. Table Precancer Testing-by Country
    • 6.6.2. Chart - Precancer Testing Growth
  • 6.7. Liquid Biopsy Prostate Cancer
    • 6.7.1. Table Prostate Cancer Testing-by Country
    • 6.7.2. Chart - Prostate Cancer Testing Growth
  • 6.8. Liquid Biopsy Melanoma
    • 6.8.1. Table Melanoma Testing-by Country
    • 6.8.2. Chart - Melanoma Testing Growth
  • 6.9. Liquid Biopsy Blood Cancer
    • 6.9.1. Table Blood Cancer Testing-by Country
    • 6.9.2. Chart - Blood Cancer Testing Growth
  • 6.10. Liquid Biopsy Other Cancer
    • 6.10.1. Table Other Cancer Testing-by Country
    • 6.10.2. Chart - Other Cancer Testing Growth

7. Global Liquid Biopsy Markets-By Type of Usage

  • 7.1. Global Market by Usage Type - Overview
    • 7.1.1. Table-Global Market by Usage Type
    • 7.1.2. Chart-Global Market by Usage Type-2019/2024 Comparison
    • 7.1.3. Chart-Global Market by Usage Type-2019
    • 7.1.4. Chart-Global Market by Usage Type - 2024
    • 7.1.4. Chart-Global Market by Usage Type-Share by Year
  • 7.2. Liquid Biopsy Screening & Early Detection
    • 7.2.1. Table Screening Testing-by Country
    • 7.2.2. Chart - Screening Testing Growth
  • 7.3. Liquid Biopsy Diagnosis
    • 7.3.1. Table Diagnosis Testing-by Country
    • 7.3.2. Chart - Diagnosis Testing Growth
  • 7.4. Liquid Biopsy Therapy Selection
    • 7.4.1. Table Therapy Selection-by Country
    • 7.4.2. Chart - Therapy Selection Growth
  • 7.5. Liquid Biopsy Monitoring
    • 7.5.1. Table Monitoring-by Country
    • 7.5.2. Chart - Monitoring Growth

8. Potential Market Opportunity Sizes

  • 8.1. Potential Cancer Screening by Country: Lung, Breast & Colorectal
  • 8.2. Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer
  • 8.3. Potential Market Size - Cancer Diagnosis
  • 8.4. Potential Market Size-Therapy Selection

Appendices

  • I. United States Medicare System: January 2019 Clinical Laboratory Fees Schedule
  • II. FDA Approved Human Genetic Tests
  • III. Pharmacogenomic Biomarkers in Drug Labeling

Table of Tables

  • Table 1: Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
  • Table 2: Market Players by Type
  • Table 3: Biopsy Sites
  • Table 4: Advantages of Liquid Biopsy in Screening Market
  • Table 5: Five Factors Driving Growth
  • Table 6: Four Factors Limiting Growth
  • Table 7: Key Diagnostic Laboratory Technology Trends
  • Table 8: Next Generation Sequencing Technologies-Speed and Cost
  • Table 9: - Global Liquid Biopsy Market by Region
  • Table 10: Global Market by Cancer Type
  • Table 11: Liquid Biopsy Breast Cancer by Country
  • Table 12: Liquid Biopsy Colorectal Cancer by Country
  • Table 13: Cervical Cancer Testing by Country
  • Table 14: Lung Cancer Testing by Country
  • Table 15: Precancer Testing by Country
  • Table 16: Prostate Cancer Testing by Country
  • Table 17: Liquid Biopsy Melanoma by Country
  • Table 18: Liquid Biopsy Blood Cancer by Country
  • Table 19: Liquid Biopsy Other Cancer Testing by Country
  • Table 20: Global Market by Usage Type
  • Table 21: Liquid Biopsy Screening by Country
  • Table 22: Liquid Biopsy Diagnosis by Country
  • Table 23: Therapy Selection Testing by Country
  • Table 24: Monitoring Testing by Country
  • Table 25: Potential Screening Market: Lung, Breast & Colorectal
  • Table 26: Potential Screening Market: Prostate, Other & All
  • Table 27: Potential Cancer Diagnosis Market Size
  • Table 28: Potential Cancer Management Market Size
  • Table 29: 2019 Laboratory Fee Schedule
  • Table 30: FDA Approved Human Genetic tests
  • Table 31: Pharmacogenomic Biomarkers

Table of Figures

  • Figure 1: Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 2: Comparison of Liquid Biopsy Classes
  • Figure 3: Characteristics of Different Vesicle Types
  • Figure 4: Percentage of World Population Over 65
  • Figure 5: 2019 Global Market Density Chart
  • Figure 6: MDx Market by Cancer - 2019 vs. 2024
  • Figure 7: Liquid Biopsy Market 2019
  • Figure 8: Liquid Biopsy Market 2024
  • Figure 9: Liquid Biopsy Share by Year
  • Figure 10: Breast Cancer Testing Growth
  • Figure 11: Colorectal Cancer Testing Growth
  • Figure 12: Cervical Cancer Testing Growth
  • Figure 13: Lung Cancer Testing Growth
  • Figure 14: Precancer Testing Growth
  • Figure 15: Prostate Cancer Testing Growth
  • Figure 16: Melanoma Testing Growth
  • Figure 17: Blood Cancer Testing Growth
  • Figure 18: Other Cancer Testing Growth
  • Figure 19: Liquid Biopsy Market by Usage Type - 2019 vs. 2024
  • Figure 20: Usage Market 2019
  • Figure 21: Usage Market 2024
Back to Top